Choice Therapeutics picks up $582K in $3M round

Thu, 07/28/2011 - 5:47am
Mass High Tech: The Journal of New England Technology

Wrentham-based wound care company Choice Therapeutics Inc. has sold $582,000 of a planned $3 million equity round, according to a filing with the U.S. Securities and Exchange Commission.

Choice Therapeutics provides medical devices and materials under the TheraBond name for burns, advanced wound care and surgical site infections, using technology designed to protect the wound while wicking excess fluids away from the wound site.

The filing indicates that the funds will be used for general corporate purposes, including $250,000 for the salary of CEO E. James Hutchens, a former executive with Natick medical devices firm Boston Scientific Corp.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.